1 Min Read
Feb 15 (Reuters) - Amicus Therapeutics Inc -
* Preclinical studies showed ATB200/AT2221 reversed cellular dysfunction, increased muscle strength over 5 month period in GAA knock-out mice Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.